15 September 2022  
EMA/CHMP/762558/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Exparel liposomal 
bupivacaine 
On 15 September 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Exparel liposomal. The marketing authorisation holder for this medicinal product is Pacira Ireland Limited. 
The CHMP adopted an extension to the existing indication for the treatment of somatic post-operative 
pain in children aged 6 years or older.  
For information, the full indication for Exparel liposomal will be as follows2: 
Exparel liposomal is indicated (see section 5.1): 
• 
• 
in adults as a brachial plexus block or femoral nerve block for treatment of post-
operative pain.  
in adults and children aged 6 years or older as a field block for treatment of somatic 
post-operative pain from small- to medium-sized surgical wounds.  
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
